Compare HubSpot Inc (HUBS) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HubSpot Inc vs State Street SPDR S&P Biotech ETF — how do they compare? HubSpot Inc trades at $228.3 (market cap $11.56B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: HubSpot Inc and State Street SPDR S&P Biotech ETF are close in size by market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, HubSpot Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold HubSpot Inc for 78 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| HUBS | XBI | |
|---|---|---|
Market Cap | $11.56B | $10.11B |
Volume | 1,891,287 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $494.58 | $169.55 |
52-Week Low | $170.39 | $104.99 |
Typical Hold Time | 78 Days | 38 Days |
Enterprise Value | $10.46B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HubSpot (HUBS) trades at $231.84, up 5.23% over the past day, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust revenue growth, improving profitability, and positive cash flow trends, supported by an AI-focused strategy unveiled at its recent Analyst Day. Analyst consensus is bullish with a $243.65 price target, though high valuation multiples and competitive pressures remain considerations.
The outlook for HUBS is positive, driven by AI integration, margin expansion targets, and consistent revenue growth. Key risks include elevated valuation metrics, potential AI-driven demand headwinds, and insider selling activity. The stock presents a growth opportunity but requires monitoring of execution against ambitious targets and competitive dynamics in the CRM software space.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
